Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



This article was originally published in Start Up

Executive Summary

Becton Dickinson's spin-off, Vyteris, has big plans for its iontophoresis transdermal drug delivery system, which actively pressures molecules to go into the body over time. Vyteris has chosen to seek approval of its use first with lidocaine, a powerful, fast-acting local anesthetic, which has been on the market for years. While it works well to desensitize skin prior to minor surgery or injection, its use is limited because it takes too long to be effective for widespread applications and doesn't go deep enough under the skin. Vyteris' transdermal lidocaine system addresses these shortcomings and has the potential to expand substantially lidocaine's market.

You may also be interested in...

Becton Dickinson's Ventures

Becton Dickinson doesn't want any technology surprises blindsiding its businesses, so it's set up both a $40 million venture fund and a technology incubator. The latter offers space and facilities to North Carolina-based start-ups, the former funding for start-ups anywhere. The only condition in both cases: common strategic interests, at least in the long-term.

Becton Dickinson at a Crossroads: Diagnostics on the Fence

BD has been doing well recently, but CEO Clateo Castellini wants to do even better--doubling revenues and profits in the next five years. That puts pressure on a company known for exploiting mature product lines. BD's diagnostics business, in particular, faces the challenge of keeping up in a rapidly consolidating segment as it goes head-to-head for the first time with the industry's heavy hitters.

Making The Most Of ACOs: How Biopharma Is Adapting To New Customer Segment

ACOs have been one of the most hyped innovations in the US health care sector this decade. The buzz may be overdone, but ACOs are now established as a different—and confusing—new customer segment for pharma. How is industry adjusting?


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts